<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is a disorder of coagulation that causes <z:mp ids='MP_0005048'>thrombosis</z:mp> as well as pregnancy-related complications, occurring due to the autoimmune production of antibodies against <z:chebi fb="0" ids="16247">phospholipid</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Full anticoagulation is the cornerstone therapy in patients with <z:mp ids='MP_0005048'>thrombosis</z:mp> history, and this can lead to major <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>During a 3-year period, 300 primary and secondary APS patients were followed up at the Rheumatology Division of the authors' University Hospital </plain></SENT>
<SENT sid="3" pm="."><plain>Of them, 255 (85%) were women and 180 (60%) were of reproductive age </plain></SENT>
<SENT sid="4" pm="."><plain>Three of them (1%) had severe hemorrhagic corpus luteum while receiving long-term anticoagulation treatment and are described in this report </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of them were taking <z:chebi fb="8" ids="10033">warfarin</z:chebi>, had elevated international normalized ratio (&gt;4.0) and required prompt blood transfusion and emergency surgery </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore, we strongly recommend that <z:hpo ids='HP_0000001'>all</z:hpo> women with APS under anticoagulation should have ovulation suppressed with either intramuscular depot-<z:chebi fb="0" ids="6716">medroxyprogesterone acetate</z:chebi> or oral <z:chebi fb="0" ids="4453">desogestrel</z:chebi> </plain></SENT>
</text></document>